IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v424y2003i6949d10.1038_nature01876.html
   My bibliography  Save this article

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

Author

Listed:
  • Nancy J. Sullivan

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Thomas W. Geisbert

    (United States Army Medical Research Institute of Infectious Diseases)

  • Joan B. Geisbert

    (United States Army Medical Research Institute of Infectious Diseases)

  • Ling Xu

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Zhi-yong Yang

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Mario Roederer

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Richard A. Koup

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Peter B. Jahrling

    (United States Army Medical Research Institute of Infectious Diseases)

  • Gary J. Nabel

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

Abstract

Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease1, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV–GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV–GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.

Suggested Citation

  • Nancy J. Sullivan & Thomas W. Geisbert & Joan B. Geisbert & Ling Xu & Zhi-yong Yang & Mario Roederer & Richard A. Koup & Peter B. Jahrling & Gary J. Nabel, 2003. "Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates," Nature, Nature, vol. 424(6949), pages 681-684, August.
    • Handle: RePEc:nat:nature:v:424:y:2003:i:6949:d:10.1038_nature01876
    DOI: 10.1038/nature01876
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature01876
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature01876?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Nicholas V. Olijnyk, 2015. "An algorithmic historiography of the Ebola research specialty: mapping the science behind Ebola," Scientometrics, Springer;Akadémiai Kiadó, vol. 105(1), pages 623-643, October.
    2. Jade Mitchell & Kara Dean & Charles Haas, 2020. "Ebola Virus Dose Response Model for Aerosolized Exposures: Insights from Primate Data," Risk Analysis, John Wiley & Sons, vol. 40(11), pages 2390-2398, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:424:y:2003:i:6949:d:10.1038_nature01876. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.